Age-related macular degeneration (AMD) is a progressive, chronic disease of the central area of the retina, which, if untreated, leads to blindness. This study aimed to compare the effectiveness of therapy using anti-VEGF drugs, namely brolucizumab and aflibercept, in patients with neovascular AMD (nAMD) during a monitoring period lasting around 20 weeks. The analysis consisted of 40 patients diagnosed with neovascular age-related macular degeneration, with 20 patients receiving aflibercept (Eylea, Bayer) at a dose of 2 mg/50 µL into the vitreous chamber at the following intervals—3 doses, 4 weeks apart, followed by a fourth dose after 8 weeks. The remaining 20 patients received brolucizumab (Beovu, Novartis) at a dose of 6 mg/50 µL, administered in the following schedule—3 initial doses, 4 weeks apart, with the administration of a fourth dose decided for each patient individually by the doctor, depending on disease activity, assessed through imaging tests. To evaluate treatment effectiveness, the following measurements were used: ‘read distance and near visual acuity’ for each eye separately using the Snellen chart; and non-invasive retinal imaging techniques—optical coherence tomography (OCT) and OCT angiography (OCTA). In patients treated using brolucizumab, during the observation period, statistically significant differences were found in the following parameters: flow area (p = 0.0277); select area (p = 0.0277); FOVEA (p = 0.0073); visus (p = 0.0064). In brolucizumab-treated patients, changes in OCT and OCTA, indicating an improvement, were already visible after the first injection of the drug, whereas in the aflibercept-treated group, changes were only visible after the fourth injection. We found a higher effectiveness of brolucizumab therapy compared to aflibercept in patients with nAMD during an observations period lasting 20 weeks. Our observations are significant, although they require further research.

No abstract

Age-related macular degeneration (AMD) is the leading cause of blindness among the elderly in the developed world. Currently, there are 4 available intravitreal anti-VEGF therapies (pagaptanib, bevacizumab ranimizumab and aflibercept). Brolucizumab is a newly developed anti-VEGF molecule for neowascular AMD treatment. Based primarily on the results of the phase III HAWK and HARRIER trias brolucizumab was recently approved in the US for the treatment of exudative (wet) AMD. In this paper we summarize the safety, visual and anatomic outcomes of brolucizumab in the treatment of neovascular AMD. The aim of the study was to evaluate the efficacy in visual function improvement of brolucizumab with aflibercept in neovascular age-related macular degeneration (AMD). Fourteen patients, aged > 50 years , with untreated, active choroidal neovascularization due to age-related macular degeneration in the study eye. Eligible participants were randomized 1:1 to intravitreal injections of brolucizumab (6mg/50 μl) or aflibercept (2mg/50 μl). Both groups received 3 monthly loading doses and were then treated every 8 weeks. Brolucizumab demonstrate non inferiority to aflibercept in BCVA change from baseline. Optical Coherence Tomography Angiography(angio-OCT, OCTA) is the latest diagnostic tool In ophthalmology. It allows to visualize blood flow in the vessels of the retina and choroid In a non invasive manner. Angio-OCT is based on technology that uses laser ligt reflection from the surface of moving red blood cells. The movement of erythrocytes enables the visualization of the flow In the blood vessels. OCTA algorithms create an images(from 3mm2 to 12mm2) that are normalny divided into four zones: superficial retinal lexus, deep retinal lexus, outer retina and choriocapillaries Brolucizumab was superior to aflibercept in visual function like contrast sensitivity and decrease of metamorphopsia. Anatomic outcomes favored brolucizumab over aflibercept.